| Literature DB >> 33911755 |
Gyeong-Hun Park1, Jeong-Hee Choi2, Sunmi Kim3, Youin Bae1.
Abstract
BACKGROUND: Despite the autologous serum skin test (ASST) and autologous plasma skin test (APST) is widely used test accessing whether a patient with chronic spontaneous urticaria (CSU) has autoreactivity or not, the clinician often encounter difficulty making correlation between the test result and clinical implications.Entities:
Keywords: Autologous plasma skin test; Autologous serum skin test; Chronic spontaneous urticaria; Chronic urticaria
Year: 2020 PMID: 33911755 PMCID: PMC7992654 DOI: 10.5021/ad.2020.32.4.280
Source DB: PubMed Journal: Ann Dermatol ISSN: 1013-9087 Impact factor: 1.444
Comparison of study variables with positive and negative autologous serum and positive test groups
| Study variable | ASST−/APST− | ASST−/APST+ | ASST+/APST− | ASST+/ASST+ | |
|---|---|---|---|---|---|
| Patients counts (n=300) | 175 | 12 | 57 | 56 | |
| Age | 35.97±12.12 | 38.08±12.18 | 34.11±12.87 | 35.29±14.28 | 0.697 |
| Sex | 0.230 | ||||
| Male | 81 (46.3) | 2 (16.7) | 26 (45.6) | 28 (50.0) | |
| Female | 94 (53.7) | 10 (83.3) | 31 (54.4) | 28 (50.0) | |
| Duration (wk) | 95.95±175.74 | 70.08±147.37 | 56.30±101.89 | 45.86±117.01 | 0.004* |
| Episode(s) of angioedema | 11 (6.3) | 2 (16.7) | 11 (19.3) | 11 (19.6) | 0.005* |
| History of atopy | 20 (11.4) | 3 (25.0) | 9 (15.8) | 5 (8.9) | 0.336 |
| Treatment level | 0.432 | ||||
| 1 | 142 (84.0) | 11 (91.7) | 50 (89.3) | 51 (92.7) | |
| 2 | 21 (12.4) | 1 (8.3) | 4 (7.1) | 2 (3.6) | |
| 3 | 3 (1.8) | 0 (0.0) | 2 (3.6) | 0 (0.0) | |
| 4 | 3 (1.8) | 0 (0.0) | 0 (0.0) | 2 (3.6) | |
| C3 (mg/dl) | 111.37±18.88 | 103.37±13.58 | 104.64±20.42 | 108.41±22.22 | 0.497 |
| C4 (mg/dl) | 26.99±7.38 | 29.66±9.60 | 26.13±5.89 | 24.93±9.18 | 0.439 |
| Total IgE (IU/ml) | 262.60±368.57 | 163.50±140.86 | 225.72±201.72 | 173.23±116.62 | 0.598 |
| Eosinophil count (%) | 2.73±1.83 | 2.85±1.51 | 2.67±1.75 | 2.29±1.46 | 0.375 |
| Platelet count (109/L) | 253.96±54.03 | 234.00±50.58 | 259.43±51.44 | 257.63±65.84 | 0.313 |
| Thyroid function test | |||||
| TSH (mU/L) | 2.04±1.74 | 1.63±1.14 | 2.24±1.94 | 4.91±16.36 | 0.460 |
| T3 (ng/dl) | 111.65±29.99 | 107.00±14.70 | 113.28±19.46 | 108.60±21.71 | 0.445 |
| Free T4 (ng/dl) | 1.28±0.35 | 1.28±0.19 | 1.27±0.18 | 1.27±0.27 | 0.812 |
| Thyroid antibodies | |||||
| Anti-TSH-R (U/L) | 0.62±1.17 | 0.70±0.38 | 0.43±0.25 | 0.48±0.27 | 0.079 |
| Anti-TPO (IU/ml) | 120.98±509.32 | 71.69±173.70 | 145.30±371.63 | 157.60±498.87 | 0.059 |
| Anti-TG (IU/ml) | 71.07±279.95 | 29.68±39.15 | 32.88±45.84 | 71.67±186.24 | 0.593 |
Values are presented as number only, number (%), or mean±standard deviation. APST: autologous plasma skin test, ASST: autologous serum skin test, −: negative, +: positive, TG: thyroglobulin, TPO: thyroid peroxidase, TSH: thyroid stimulating hormone, TSH-R: thyroid stimulating hormone receptor, IgE: immunoglobuline E. *p-value of <0.05.
Univariable analysis for the association between autologous serum and plasma skin test results and clinical and laboratory characteristics in chronic spontaneous urticaria
| Variable | Category | ASST | APST | ||
|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | ||||
| Age | 0.99 (0.97~1.01) | 0.349 | 1.00 (0.98~1.02) | 0.877 | |
| Sex | 0.567 | 0.771 | |||
| Male | Reference | Reference | |||
| Female | 0.87 (0.55~1.39) | 0.567 | 1.08 (0.63~1.88) | 0.771 | |
| Eosinophil count | 0.91 (0.79~1.05) | 0.225 | 0.88 (0.73~1.05) | 0.178 | |
| TSH level | 1.07 (0.99~1.26) | 0.383 | 1.05 (0.99~1.22) | 0.313 | |
| T3 level | 1.00 (0.99~1.01) | 0.899 | 0.99 (0.98~1.01) | 0.442 | |
| fT4 level | 0.93 (0.31~2.37) | 0.875 | 0.93 (0.24~2.64) | 0.907 | |
| ANA positivity | 0.142 | 0.848 | |||
| 0 | Reference | Reference | |||
| 1 | 0.37 (0.14~0.87) | 0.022 | 0.65 (0.22~1.62) | 0.376 | |
| 2 | 0.78 (0.13~3.60) | 0.754 | 0.83 (0.08~4.27) | 0.837 | |
| 3 | 0.47 (0.00~8.88) | 0.625 | 1.01 (0.01~19.26) | 0.994 | |
| C3 level | 0.99 (0.97~1.01) | 0.273 | 0.99 (0.97~1.01) | 0.471 | |
| C4 level | 0.97 (0.92~1.01) | 0.173 | 0.99 (0.94~1.04) | 0.639 | |
| Treatment level | 0.330 | 0.213 | |||
| 1 | Reference | Reference | |||
| 2 | 0.41 (0.15~1.00) | 0.064 | 0.42 (0.11~1.19) | 0.109 | |
| 3 | 1.01 (0.13~6.20) | 0.991 | 0.28 (0.00~2.53) | 0.308 | |
| 4 | 1.01 (0.13~6.20) | 0.991 | 2.20 (0.36~11.57) | 0.363 | |
| Angioedema | 0.002 | 0.033 | |||
| Absent | Reference | Reference | |||
| Present | 3.24 (1.58~6.89) | 0.002 | 2.26 (1.05~4.71) | 0.033 | |
| History of atopy | 0.911 | 0.799 | |||
| Absent | Reference | Reference | |||
| Present | 0.96 (0.46~1.92) | 0.911 | 0.90 (0.37~1.98) | 0.799 | |
| High TPO | 0.470 | 0.754 | |||
| Absent | Reference | Reference | |||
| Present | 1.36 (0.58~3.08) | 0.470 | 1.17 (0.41~2.92) | 0.754 | |
| High TG | 0.269 | 0.212 | |||
| Absent | Reference | Reference | |||
| Present | 0.63 (0.27~1.38) | 0.269 | 0.50 (0.14~1.34) | 0.212 | |
| High TSH-R | 0.129 | 0.413 | |||
| Absent | Reference | Reference | |||
| Present | 0.17 (0.00~1.51) | 0.129 | 0.35 (0.00~3.15) | 0.413 | |
| Platelet count | 1.21 (0.79~1.85) | 0.389 | 0.95 (0.57~1.55) | 0.829 | |
| Total IgE level | 0.93 (0.82~1.02) | 0.147 | 0.84 (0.70~0.98) | 0.057 | |
| Disease duration | 0.79 (0.63~0.95) | 0.025 | 0.81 (0.61~1.01) | 0.099 | |
APST: autologous plasma skin test, ASST: autologous serum skin test, ANA: antinuclear antibody, OR: odd ratio, CI: confidence interval, TG: thyroglobulin, TPO: thyroid peroxidase, TSH: thyroid stimulating hormone, TSH-R: thyroid stimulating hormone receptor, IgE: immunoglobuline E.
Multivariable analysis for the association between autologous serum and plasma skin test result and age, disease duration, angioedema in chronic spontaneous urticaria
| Variable | Category | ASST | APST | ||
|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | ||||
| Age (yr) | <0.001 | 0.421 | |||
| 30 to <45 | Reference | Reference | |||
| <30 | 3.00 (1.69~5.39) | <0.001 | 1.45 (0.76~2.78) | 0.259 | |
| ≥45 | 2.49 (1.32~4.72) | 0.005 | 1.48 (0.71~3.01) | 0.286 | |
| Duration (wk) | 0.038 | 0.031 | |||
| <8 | Reference | Reference | |||
| 8 to <14 | 0.65 (0.33~1.29) | 0.220 | 1.00 (0.49~2.06) | 0.998 | |
| 14 to <52 | 0.59 (0.28~1.23) | 0.159 | 0.68 (0.30~1.51) | 0.346 | |
| ≥52 | 0.35 (0.17~0.71) | 0.004 | 0.32 (0.13~0.74) | 0.009 | |
| Angioedema | 0.013 | 0.107 | |||
| Absent | Reference | Reference | |||
| Present | 2.63 (1.23~5.78) | 0.013 | 1.88 (0.85~4.02) | 0.107 | |
APST: autologous plasma skin test, ASST: autologous serum skin test, OR: odd ratio, CI: confidence interval. Age groups were divided into three groups based on 30 and 45 years old. Duration group were divided into four groups based on 8, 14, 52 weeks.
Fig. 1Predicted positivity of ASST and APST by study variables by using generalized additive model. (A, B) By age (C, D) by disease duration (E, F) by total IgE level. APST: autologous plasma skin test, ASST: autologous serum skin test, IgE: immunoglobuline E.
Fig. 2Scatter plot of (A) diameters of the induration of serum (horizontal axis) and plasma (vertical axis) injection sites (B) differences in diameters of the induration between serum and saline injection sites (horizontal axis) and those between plasma and saline injection sites (vertical axis).
Concordance correlation coefficients of recorded diameter of serum, plasma, and saline in the study subjects
| Variable | Serum | Plasma | Saline | Serum–saline |
|---|---|---|---|---|
| Plasma | 0.66 (0.58~0.73) | |||
| Saline | 0.32 (0.24~0.40) | 0.59 (0.50~0.67) | ||
| Serum–Saline | 0.64 (0.59~0.69) | 0.36 (0.26~0.45) | −0.16 (−0.29~−0.02) | |
| Plasma–Saline | 0.25 (0.20~0.31) | 0.45 (0.38~0.51) | −0.13 (−0.25~0.00) | 0.55 (0.44~0.65) |
Values are presented as odd ratio (95% confidence interval).